Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Ophthalmologic Manifestations of Atopic Dermatitis Follow-up

  • Author: R Scott Lowery, MD; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Mar 13, 2014
 

Further Outpatient Care

See the list below:

  • Prophylaxis against scratching should be taken.
    • Scratching the lesions can worsen them and lead to the lichenification process characteristic of long-standing disease.
    • Corneal abrasions and further eye irritation also may occur. Antihistamines, mast-cell stabilizers, and corticosteroids will aid in reducing the itching but may require some time to take effect.
    • Nails should be kept clean and trimmed.
    • In pediatric patients, mittens may be used at night or even daily, when possible, if itching and scratching are severe.
Next

Deterrence/Prevention

See the list below:

  • Stress control, avoidance of allergens (most commonly dust mites, peanuts, egg, milk, fish, rice, soy, and wheat), and irritants (particularly chemicals, soaps, heat, humidity, wool, and acrylic) may help control the disease.
Previous
Next

Complications

See the list below:

  • The use of corticosteroids is fraught with potential ocular and systemic complications. In particular, cataract formation, glaucoma development, and potential corneal thinning must all be considered when deciding to use steroids for this disease. Long-term use should be avoided if at all possible.
Previous
Next

Prognosis

See the list below:

  • The prognosis is good if the inflammation can be kept under control with therapy. Patients need to understand that atopic disease cannot be cured, but rather controlled. However, some patients have such severe disease that treatment will not prevent vision loss and other potential complications.
Previous
Next

Patient Education

See the list below:

Previous
 
Contributor Information and Disclosures
Author

R Scott Lowery, MD Associate Professor of Ophthalmology, Department of Pediatric Ophthalmology and Strabismus, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

R Scott Lowery, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, Arkansas Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Ophthalmological Society, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, International Society of Refractive Surgery, Cornea Society, Eye Bank Association of America

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, Allergan, Bausch & Lomb, Bio-Tissue, Shire, TearScience, TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Allergan, Bausch & Lomb, Bio-Tissue, TearScience.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Jack L Wilson, PhD Distinguished Professor, Department of Anatomy and Neurobiology, University of Tennessee Health Science Center College of Medicine

Jack L Wilson, PhD is a member of the following medical societies: American Association of Anatomists, American Heart Association, American Association of Clinical Anatomists

Disclosure: Nothing to disclose.

References
  1. Rapoza PA, Chandler JW. Atopic dermatitis. Weingeist T, Gould D, eds. The Eye in Systemic Disease. Philadelphia: Lippincott; 1990. 606-609.

  2. Shen CP, Xing H, Ma L. [Research advances in atopic dermatitis]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Feb. 31(1):103-6. [Medline].

  3. Jung T, Stingl G. Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. J Allergy Clin Immunol. 2008 Dec. 122(6):1074-81. [Medline].

  4. Bezan DJ. Eye itch. Bezan DJ, Larussa FP, Nishimoto JH, et al, eds. Differential Diagnosis in Primary Eye Care. Boston: Butterworth-Heinemann; 1999. 67-71.

  5. Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol. 2009 Jan-Feb. 26(1):14-22. [Medline].

  6. Bielory B, Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin North Am. 2010 Aug. 30(3):323-36. [Medline].

  7. Cornish KS, Gregory ME, Ramaesh K. Systemic cyclosporin A in severe atopic keratoconjunctivitis. Eur J Ophthalmol. 2010 Sep-Oct. 20(5):844-51. [Medline].

  8. Anderson PC, Dinulos JG. Atopic dermatitis and alternative management strategies. Curr Opin Pediatr. 2009 Feb. 21(1):131-8. [Medline].

  9. Ricci G, Dondi A, Patrizi A, Masi M. Systemic therapy of atopic dermatitis in children. Drugs. 2009. 69(3):297-306. [Medline].

  10. Kaujalgi R, Handa S, Jain A, Kanwar AJ. Ocular abnormalities in atopic dermatitis in Indian patients. Indian J Dermatol Venereol Leprol. 2009 Mar-Apr. 75(2):148-51. [Medline].

  11. Clark RAF, Kristal L. Atopic dermatitis. Sams J, Lynch PJ, eds. Principles and Practice of Dermatology. 2nd ed. New York: Churchill Livingstone Inc; 1996. 403-418.

  12. Friedlander MH. Diseases affecting the eye and the skin. Allergy and Immunology of the Eye. 2nd ed. 1993. 75-106.

  13. Friedlander MH. Atopic dermatitis. Current Ocular Therapy. 5th ed. Philadelphia: WB Saunders Co; 2000. 143-144.

  14. Furue M, Terao H, Moroi Y, et al. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J Dermatol. 2004 Apr. 31(4):277-83. [Medline].

  15. Guin JD. Eyelid dermatitis: experience in 203 cases. J Am Acad Dermatol. 2002 Nov. 47(5):755-65. [Medline].

  16. Hanifin JM. Atopic dermatitis: broadening the perspective. J Am Acad Dermatol. 2004 Jul. 51(1 Suppl):S23-4. [Medline].

  17. Kanski JJ. Disorders of the conjunctiva. Clinical Ophthalmology. 4th ed. Boston: Butterworth-Heinemann; 1999. 69-71.

  18. Liesegang TJ. Atopic keratoconjunctivitis. Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St. Louis: Mosby; 1996. 376-390.

  19. Roy FH. Ocular Differential Diagnosis. 7th ed. Philadelphia: Williams & Wilkins; 2002.

  20. Shelley WB, Shelley EB. Atopic dermatitis. Advanced Dermatologic Diagnosis. Philadelphia: WB Saunders Co; 1992. 285-291.

  21. Uchio E, Miyakawa K, Ikezawa Z, Ohno S. Systemic and local immunological features of atopic dermatitis patients with ocular complications. Br J Ophthalmol. 1998 Jan. 82(1):82-7. [Medline].

  22. Weisbecker CA, Fraunfelder FT, Rhee D. Physicians' Desk Reference for Ophthalmology. 28th ed. Oradell, NJ: Medical Economics Co; 2000.

  23. Zimmerman TJ, Kulkarni PS, Meredith TA. Steroids in ocular therapy, antibiotics and antifungals, antiallergic therapies. Zimmerman TJ, Kooner KS, Shariv M, Fechtner RD, eds. Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven; 1997. 61-74, 363-385, 609-633,683-701, 801-804.

Previous
Next
 
Typical atopic dermatitis on the face of an infant.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.